{
  "id": 20311817,
  "title": "Innoviva stock hits 52-week low at 18.6 USD",
  "url": "https://urgent.news/2026/11/16/innoviva-stock-hits-52-week-low-at-18-6-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T18:39:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/innoviva-stock-hits-52week-low-at-186-usd-93CH-5030703"
  },
  "original_language": "en",
  "account": "Innoviva Inc. witnessed its stock plunge to a 52-week low of 18.6 USD, reflecting a steep 14.93% decline over the past year. Despite this steep fall, some analysts perceive the stock as undervalued, with a P/E ratio of 7.37 and a PEG ratio of 0.1. The Fair Value assessment indicates potential upside, positioning Innoviva on the platform’s Most Undervalued list. The company's struggles are attributed to financial adjustments and strategic shifts, but InvestingPro Tips highlight a strong free cash flow yield of 14% and a low P/E ratio relative to near-term earnings growth. Inova Technology, which owns Innoviva, has been backed by Oppenheimer with an Outperform rating and a price target of $35.00, while Cantor Fitzgerald has reconfirmed its overweight rating with a target of $34.00. Both firms see potential in Inova's rapidly growing critical care and infectious disease platform, as well as its healthcare assets. This transformation from a royalty-only business to a diversified biopharmaceutical company has been underscored by a recent webinar hosted by Cantor Fitzgerald.",
  "summary": null,
  "key_points": [
    "Innoviva stock drops to 52-week low of 18.6 USD, a 14.93% decline",
    "Analysts see potential upside despite steep fall, citing low P/E ratio",
    "Inova Technology backed by Oppenheimer with Outperform rating and $35.00 target"
  ],
  "editors_take": "The disconnect between Innoviva’s plunging share price and optimistic analyst targets suggests a significant valuation gap as the company transitions from a royalty-only model into a diversified biopharmaceutical entity.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}